Common use of Time to Complete Clause in Contracts

Time to Complete. North Coast will complete the Services and provide the Deliverables with respect to an Optional Candidate as described in Section 2.3 within [†]. † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION This Initial Research Plan is accepted and acknowledged by each Party through the signature of its authorized representative below, and is effective as of the date first set forth above in this Initial Research Plan. NORTH COAST BIOLOGICS LLC OMEROS CORPORATION By: /s/ Xxxxxx Xxxxx Name: Xxxxxx Xxxxx By: Name: /s/ Xxxxxxx X. Xxxxxxxxx Xxxxxxx X. Xxxxxxxxx, M.D. Title: President Title: Chairman & CEO † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION Exhibit C to Omeros Corporation AGREEMENT FOR ANTIBODY DEVELOPMENT SERVICES FORM OF ADDITIONAL TARGET RESEARCH PLAN RESEARCH PLAN FOR ANTIBODIES TO [ADDITIONAL TARGET] This Research Plan for Antibodies to [ADDITIONAL TARGET] is dated as of [XXXX] and is between Omeros Corporation (“Omeros”) and North Coast Biologics LLC (“North Coast”) and constitutes an “Additional Target Research Plan” under the Agreement for Antibody Development dated October 31, 2008 between Omeros and North Coast (the “Development Agreement”). Capitalized terms used but not defined in this Additional Target Research Plan shall have the meanings given to them in the Development Agreement.

Time to Complete. North Coast will complete the Services and provide the Deliverables with respect to an Optional Candidate as described in Section 2.3 within [†]. † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION This Initial Additional Target Research Plan is accepted and acknowledged by each Party through the signature of its authorized representative below, and is effective as of the date first set forth above in this Initial Additional Target Research Plan. NORTH COAST BIOLOGICS LLC OMEROS CORPORATION By: /s/ Xxxxxx Xxxxx Name: Xxxxxx Xxxxx By: Name: /s/ Xxxxxxx X. Xxxxxxxxx Xxxxxxx X. Xxxxxxxxx, M.D. Name: Title: President Title: Chairman & CEO † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION Exhibit C D to Omeros Corporation AGREEMENT FOR ANTIBODY DEVELOPMENT SERVICES FORM LIST OF ADDITIONAL TARGET RESEARCH PLAN RESEARCH PLAN NORTH COAST PATENTS Application No. [†] Title: DISCOVERY AND GENERATION OF HIGH AFFINITY, FUNCTIONAL THERAPEUTIC OR DIAGNOSTIC PROTEINS Filing Date: [†] † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR ANTIBODIES TO [ADDITIONAL TARGET] This Research Plan for Antibodies to [ADDITIONAL TARGET] is dated as of [XXXX] and is between Omeros Corporation (“Omeros”) and North Coast Biologics LLC (“North Coast”) and constitutes an “Additional Target Research Plan” under the Agreement for Antibody Development dated October 31, 2008 between Omeros and North Coast (the “Development Agreement”). Capitalized terms used but not defined in this Additional Target Research Plan shall have the meanings given to them in the Development Agreement.CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION